215 related articles for article (PubMed ID: 30677777)
61. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
62. Malignant prolactinoma: case report and review of the literature.
Kars M; Roelfsema F; Romijn JA; Pereira AM
Eur J Endocrinol; 2006 Oct; 155(4):523-34. PubMed ID: 16990651
[TBL] [Abstract][Full Text] [Related]
63. Mucocele-like formation leading to neurological symptoms in prolactin-secreting pituitary adenomas under dopamine agonist therapy.
Abe T; Lüdecke DK
Surg Neurol; 1999 Sep; 52(3):274-9. PubMed ID: 10511086
[TBL] [Abstract][Full Text] [Related]
64. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
[TBL] [Abstract][Full Text] [Related]
65. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.
Caccavelli L; Feron F; Morange I; Rouer E; Benarous R; Dewailly D; Jaquet P; Kordon C; Enjalbert A
Neuroendocrinology; 1994 Sep; 60(3):314-22. PubMed ID: 7969790
[TBL] [Abstract][Full Text] [Related]
66. Current management of prolactinomas.
Nomikos P; Buchfelder M; Fahlbusch R
J Neurooncol; 2001 Sep; 54(2):139-50. PubMed ID: 11761431
[TBL] [Abstract][Full Text] [Related]
67. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
[TBL] [Abstract][Full Text] [Related]
68. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics.
Gürlek A; Karavitaki N; Ansorge O; Wass JA
Eur J Endocrinol; 2007 Feb; 156(2):143-53. PubMed ID: 17287403
[TBL] [Abstract][Full Text] [Related]
69. Relationship between expression of vascular endothelial growth factor and the proliferation of prolactinomas.
Li N; Jiang Z
Clin Neurol Neurosurg; 2017 Feb; 153():102-106. PubMed ID: 28110235
[TBL] [Abstract][Full Text] [Related]
70. Hyperprolactinemia and prolactinomas.
Mancini T; Casanueva FF; Giustina A
Endocrinol Metab Clin North Am; 2008 Mar; 37(1):67-99, viii. PubMed ID: 18226731
[TBL] [Abstract][Full Text] [Related]
71. Hyperprolactinemia/Prolactinomas in the Postmenopausal Period: Challenges in Diagnosis and Management.
Pekić S; Medic Stojanoska M; Popovic V
Neuroendocrinology; 2019; 109(1):28-33. PubMed ID: 30347396
[TBL] [Abstract][Full Text] [Related]
72. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
Vroonen L; Jaffrain-Rea ML; Petrossians P; Tamagno G; Chanson P; Vilar L; Borson-Chazot F; Naves LA; Brue T; Gatta B; Delemer B; Ciccarelli E; Beck-Peccoz P; Caron P; Daly AF; Beckers A
Eur J Endocrinol; 2012 Nov; 167(5):651-62. PubMed ID: 22918301
[TBL] [Abstract][Full Text] [Related]
73. Long-term management of prolactinomas.
Schlechte JA
J Clin Endocrinol Metab; 2007 Aug; 92(8):2861-5. PubMed ID: 17682084
[TBL] [Abstract][Full Text] [Related]
74. The importance of dopamine in the pathogenesis of experimental prolactinomas.
el-Azouzi M; Hsu DW; Black PM; Jolesz F; Hedley-Whyte ET; Klibanski A; Zervas NT
J Neurosurg; 1990 Feb; 72(2):273-81. PubMed ID: 1967303
[TBL] [Abstract][Full Text] [Related]
75. [Prolactinoma in man: clinical and histological characteristics].
Trouillas J; Delgrange E; Jouanneau E; Maiter D; Guigard MP; Donckier J; Perrin G; Jan M; Tourniaire J
Ann Endocrinol (Paris); 2000 Sep; 61(3):253-7. PubMed ID: 10970951
[TBL] [Abstract][Full Text] [Related]
76. Phosphorylation of kinase insert domain receptor by cyclin-dependent kinase 5 at serine 229 is associated with invasive behavior and poor prognosis in prolactin pituitary adenomas.
Xie W; Liu C; Wu D; Li Z; Li C; Zhang Y
Oncotarget; 2016 Aug; 7(32):50883-50894. PubMed ID: 27438154
[TBL] [Abstract][Full Text] [Related]
77. Giant prolactinomas presenting as skull base tumors.
Minniti G; Jaffrain-Rea ML; Santoro A; Esposito V; Ferrante L; Delfini R; Cantore G
Surg Neurol; 2002 Feb; 57(2):99-103; discussion 103-4. PubMed ID: 11904200
[TBL] [Abstract][Full Text] [Related]
78. Differential actions of the dopamine agonist bromocriptine on growth of SMtTW tumors exhibiting a prolactin and/or a somatotroph cell phenotype: relation to dopamine D2 receptor expression.
Trouillas J; Chevallier P; Remy C; Rajas F; Cohen R; Calle A; Hooghe-Peters EL; Rousset B
Endocrinology; 1999 Jan; 140(1):13-21. PubMed ID: 9886801
[TBL] [Abstract][Full Text] [Related]
79. Therapy of endocrine disease: the challenges in managing giant prolactinomas.
Maiter D; Delgrange E
Eur J Endocrinol; 2014 Jun; 170(6):R213-27. PubMed ID: 24536090
[TBL] [Abstract][Full Text] [Related]
80. Malignant prolactinoma: a rare case report.
Trivedi P; Gupta A; Pasricha S; Patel D
Neurol India; 2010; 58(5):778-80. PubMed ID: 21045511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]